Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2016

View Archived Issues

Vigilant Biosciences launches OncAlert Labs OraMark test for early detection of oral cancer

Audentes gene therapy AT-342 granted U.S. orphan status for Crigler Najjar syndrome

FDA grants fast track designation for VT-1129

Anika Therapeutics announces European commercial launch of Cingal

Eyegate Pharmaceuticals' EGP-437 shows positive response in phase Ib/IIa study

QR-110 from ProQR Therapeutics receives U.S. and E.U. orphan drug designations

Actelion Pharmaceuticals patents antibacterials

GlaxoSmithKline discloses SIRT1 activators

Novartis reports development of BTK inhibitors

NeuroSearch signs agreement with Saniona for the transfer of ACR-325 and ACR-343

Hangzhou Bensheng Pharmaceutical presents anticancer agents

FDA approves Roche's cobas EGFR Mutation Test v2

CSIR announces PI3Kalpha inhibitors

First-in-class compound for IBD

FDA approves Netspot to help detect neuroendocrine tumors

Tafinlar and Mekinist launched in Japan

CCX-168 receives EMA PRIME designation for AAV

Galena's Neuvax gains FDA fast track designation for breast cancer

Can-Fite reaches agreement with EMA for piclidenoson phase III trial

Gene expression in obesity

FDA accepts Curis' IND for CA-170

GeoVax's Ebola vaccine demonstrates complete protection against EBV challenge

EC gives orphan drug designation to AB-569 for cystic fibrosis

Actinium Pharmaceuticals reports phase I trial results for Actimab-A

GSK brings forward planned NDA submission for fluticasone furoate/umeclidinium/vilanterol in COPD

Oncolytic virus PVS-RIPO given FDA orphan status for glioma

Kite Pharma granted access to European PRIME initiative for KTE-C19 in DLBCL

Selinexor is tolerable in combination with fludarabine and cytarabine

Alexion's ALXN-1210 awarded European orphan drug designation for PNH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...